GLP1R and metabolic dysfunction-associated steatohepatitis: The global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) and its advanced form, metabolic dysfunction-associated steatohepatitis (MASH), continues to rise with limited therapeutic options available, except for the conditionally approved resmetirom (1) and some promising candidates in the pipeline, such as glucagon-like peptide-1 receptor (GLP1R) agonists (2).